Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Background Although several important studies have been performed in hypertensive type 2 diabetic patients, it is not known whether lowering blood pressure in normotensive (BP Methods The current study was a prospective, randomized controlled trial in normotensive type 2 diabetic subjects. The subjects were randomized to intensive (10mm Hg below the baseline DBP) versus moderate (80 to 89mm Hg) DBP control. Patients in the moderate therapy group were given placebo, while the patients randomized to intensive therapy received either nisoldipine or enalapril in a blinded manner as the initial antihypertensive medication. The primary end point evaluated was the change in creatinine clearance with the secondary endpoints consisting of change in urinary albumin excretion, progression of retinopathy and neuropathy and the incidence of cardiovascular disease. Results The mean follow-up was 5.3 years. Mean BP in the intensive group was 128 ± 0.8/75 ± 0.3mm Hg versus 137 ± 0.7/81 ± 0.3mm Hg in the moderate group, P P = 0.43), a lower percentage of patients in the intensive group progressed from normoalbuminuria to microalbuminuria ( P = 0.012) and microalbuminuria to overt albuminuria ( P = 0.028). The intensive BP control group also demonstrated less progression of diabetic retinopathy ( P = 0.019) and a lower incidence of strokes ( P = 0.03). The results were the same whether enalapril or nisoldipine was used as the initial antihypertensive agent. Conclusion Over a five-year follow-up period, intensive (∼128/75mm Hg) BP control in normotensive type 2 diabetic patients: ( 1 ) slowed the progression to incipient and overt diabetic nephropathy; ( 2 ) decreased the progression of diabetic retinopathy; and ( 3 ) diminished the incidence of stroke.